key: cord-0904774-0zqpklwt
authors: Miller, Jonathan; Cantor, Amanda; Zachariah, Philip; Ahn, Danielle; Martinez, Mercedes; Margolis, Kara
title: Gastrointestinal symptoms as a major presentation component of a novel multisystem inflammatory syndrome in children (MIS-C) that is related to COVID-19: a single center experience of 44 cases
date: 2020-06-04
journal: Gastroenterology
DOI: 10.1053/j.gastro.2020.05.079
sha: 05914213512dd63f0c88ab55eb324f9c0738d7dd
doc_id: 904774
cord_uid: 0zqpklwt

nan

Introduction: Until recently, the clinical course of coronavirus disease 2019 (COVID-19) in children has been reported to be largely mild. 1, 2 Recently, it has become evident that a subset of children exposed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can become critically ill with a condition now referred to as multisystem inflammatory syndrome in children (MIS-C), characterized by systemic hyperinflammation with fever and multi-system organ dysfunction. 3 Gastrointestinal symptoms are increasingly recognized to be associated with the presentation of MIS-C, potentially confusing the diagnosis of MIS-C with other common, less toxic gastrointestinal infections and even inflammatory bowel disease. In the first published correspondence describing MIS-C in eight patients from the United Kingdom, 100% presented with GI symptoms. 4 Similarly 6 of 10 patients from an Italian cohort had GI issues. 5 This is In contrast to adults, who most commonly present with respiratory symptoms, and report GI symptoms in <10-15% of cases. 6, 7 We examined whether similar presentations and prevalence extended to our comparatively larger U.S. cohort of 44 patients (<21 years old) with MIS-C. Table 1) . Table 1 . GI symptoms were a presenting symptom in 84.1% of cases and were most often accompanied by fever (100%) and rash (70.5%). In contrast to adults, only 25% required supplemental oxygen and one was intubated. Interestingly, 29.5% had presented within seven days prior to admission at an emergency room or urgent care center for less severe symptoms such as fever and GI symptoms mimicking a viral gastroenteritis (e.g., nausea, vomiting, diarrhea) but without other systemic symptoms. Of the 27% of patients who had a stool infectious PCR panel performed, 0% had an identified infection. Patients who initially presented with GI symptoms did not differ by sex or BMI compared to those patients that presented without.

Overall, the majority of cases at admission had markedly elevated inflammatory markers ESR (median 59), CRP (median 146.5) and mildly decreased albumin (median 3.7).

Transaminases (ALT and/or AST) were elevated in 52.3% and lipase was elevated >3 times upper limit of normal in only one patient (Table 1) .

Abdominal imaging studies were performed in 34.1% of patients (n=15) ( Table S1) .

Findings included mesenteric adenitis (n=2), biliary sludge or acalculous cholecystitis (n=6), and ascites (n=6). Three (20.0%) had normal abdominal imaging. In three patients, ultrasound (US) or magnetic resonance imaging (MRI) revealed bowel wall thickening (n=3), which raised concern for inflammatory bowel disease, though the accompanying clinical manifestations were not typical of IBD (Table 1) . Of these patients, one had intense right lower quadrant (RLQ) abdominal pain, fever and rash with MRI findings of severe concentric mural thickening, edema, and hyper-enhancement of a short segment of terminal ileum with extensive mesenteric fat edema, as well as similar mural thickening in the rectosigmoid colon (presenting CRP 184.7, ESR 56, albumin 3.7) (representative image in Figure S1 , area highlighted by red arrow).

with highly elevated CRP and mildly decreased to normal albumin levels.

Steroids were administered to 42 patients (95.5%) as methylprednisolone and/or hydrocortisone. Other therapies included IVIG (81.8%) and anakinra (18.2%), with 90.1% receiving anticoagulation. At the time of this report, all except one were discharged, none required mechanical circulatory support, and one patient required renal replacement therapy.

There were no fatalities.

Discussion: GI signs and symptoms appear prominently as presenting features of MIS-C. 4, 5, 8 These data suggest that the vast majority of patients who develop this condition present with GI symptoms mimicking GI infection or even inflammatory bowel disease. MIS-C should thus be considered in patients with prominent GI symptoms and a history of recent SARS-CoV-2 exposure or infection. Although not uniformly, MIS-C can differ from these other conditions in both its clinical co-morbidities as well as extremely high inflammatory markers. Amongst followup for other potential sequelae of organ dysfunction, long-term follow-up for the GI manifestations in some of these patients may warrant surveillance for IBD. 

SARS-CoV-2 Infection in Children

Screening and Severity of Coronavirus Disease 2019 (COVID-19) in Children in

Inflammatory Syndrome in Children (MIS-C) Associated with Coronavirus Disease 2019 (COVID-1919). Emergency Response and Preparedness website

Hyperinflammatory shock in children during COVID-19 pandemic

An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study

Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis

AGA Institute Rapid Review of the GI and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19

Gastrointestinal features in children with COVID-19: an observation of varied presentation in eight children